Pathoblockers or antivirulence drugs as a new option for the treatment of bacterial infections

Scholarly Works

• Shafiei, R.; Alhayek, A.; Hiller, L.; Latta, L.; Neu, T.; Aljohmani, A.; Abdollahibiroun, S.; Schönborn, E.-M.; Yildiz, D.; Schneider-Daum, N.; Lehr, C.-M.; Haupenthal, J.; Hirsch, A. K. H. Exploring the Role of Pseudomonas aeruginosa Elastase in Lung Epithelial Barrier Dysfunction: Advancing toward Antivirulence Therapies. ACS Infectious Diseases 2026. doi:10.1021/acsinfecdis.5c00915
• Pietrella, A.; Paris, I.; Migliorini, C.; Morelli, M.; Carpentieri, A.; Matricardi, P.; Di Meo, C.; Papa, R. Hyaluronan and gellan nanohydrogels exhibit an unexpected activity in hampering Staphylococcus epidermidis biofilm. Journal of controlled release : official journal of the Controlled Release Society 2026, 394, 114861. doi:10.1016/j.jconrel.2026.114861
• Taudte, N.; Liebe, L.; Jänckel, N.; Ramsbeck, D.; Schilling, S.; Potempa, J.; Eick, S.; Buchholz, M. Novel small molecule targeting PgQC reduces Porphyromonas gingivalis virulence. Frontiers in oral health 2026, 7, 1716188. doi:10.3389/froh.2026.1716188
• Rox, K. Exploiting Pharmacokinetic/Pharmacodynamic Methods for Optimizing and Accelerating Drug Development of Innovative Anti-Infectives. ChemMedChem 2026, 21, e202500743. doi:10.1002/cmdc.202500743
• Bista, S.; Brangulis, K.; Bhattachan, B.; Foor, S. D.; Ronzetti, M. H.; Jain, S.; Miller, J.; Subramanion, J. L.; Kitsou, C.; Rana, V. S.; Rai, G.; Zakharov, A. V.; Simeonov, A.; Baljinnyam, B.; Pal, U. Targeting of interaction between BB0323-BB0238 informs new paradigms in Lyme disease therapeutics. PLoS pathogens 2026, 22, e1013805. doi:10.1371/journal.ppat.1013805
• Vijayan, N. K.; Tanimu, H.; Sukumaran, B. O. Quorum quenching pathoblockers from bacteria: an alternative approach for bacterial infection management. Folia microbiologica 2025. doi:10.1007/s12223-025-01395-w
• Rosencrantz, S.; Tang, J. S. J.; Koenig, K.; Chea, S.; Rosencrantz, R. R. Glyco-Nanogels for Modulating Pseudomonas aeruginosa Biofilm. Macromolecular rapid communications 2025, e00807. doi:10.1002/marc.202500807
• Imberty, A. Lectins in the sweet strategy of lung pathogens: from structural glycobiology to design of glycomimetic pathoblockers. Comptes Rendus. Chimie 2025, 28, 873–886. doi:10.5802/crchim.425
• Wojtczak, K.; Gillon, E.; Bura, D.; Richmond, K.; Joyce, M.; Caraher, E.; Kessie, K.; Velasco-Torrijos, T.; Trujillo, C.; Imberty, A.; Kavanagh, K.; Cooke, G.; Byrne, J. P. Antiadhesive glycoconjugate metal complexes targeting pathogens Pseudomonas aeruginosa and Candida albicans. Organic & biomolecular chemistry 2025, 23, 9950–9964. doi:10.1039/d5ob00970g
• Elanany, A. A.; Khalifa, A. G.; Attia, A. S. Antivirulence drugs against Acinetobacter baumannii: where do they stand?. World journal of microbiology & biotechnology 2025, 41, 424. doi:10.1007/s11274-025-04593-3
• Di Leo, R.; Crispino, E.; Cuffaro, D.; Maisetta, G.; Bertacca, A.; Bianchi, M.; Batoni, G.; Wushur, I.; Rahman, F. A.; Winberg, J.-O.; Sylte, I.; Rossello, A.; Nuti, E. Identification of novel N-benzyloxy-amino acid hydroxamates as inhibitors of the virulence factor LasB from Pseudomonas aeruginosa. RSC medicinal chemistry 2025, 16, 4973–4996. doi:10.1039/d5md00393h
• Yu, X.-Q.; Gong, Y.-W.; Tian, J.-Q.; Peng, C.; Niu, S.-M.; Feng, H.-Z.; You, C.-G.; Wang, Z.-P. Cross-talk between Pseudomonas aeruginosa and urinary tract infections. World journal of urology 2025, 43, 380. doi:10.1007/s00345-025-05758-3
• Thiemann, M.; Zimmermann, M.; Diederich, C.; Zhan, H.; Lebedev, M.; Pletz, J.; Baumgarten, J.; Handke, M.; Müsken, M.; Breinbauer, R.; Krasteva-Christ, G.; Zanin, E.; Empting, M.; Schiedel, M.; Kunick, C.; Blankenfeldt, W. From Bones to Bugs: Structure-Based Development of Raloxifene-Derived Pathoblockers That Inhibit Pyocyanin Production in Pseudomonas aeruginosa. Journal of medicinal chemistry 2025, 68, 7390–7420. doi:10.1021/acs.jmedchem.4c03065
• Wu, Y.; Wen, F.; Gou, S.; Ran, Q.; Chu, Y.; Ma, W.; Zhao, K. Multifaceted quorum-sensing inhibiting activity of 3-(Benzo[d][1,3]dioxol-4-yl)oxazolidin-2-one mitigates Pseudomonas aeruginosa virulence. Virulence 2025, 16, 2479103. doi:10.1080/21505594.2025.2479103
• Vazquez-Armenta, F. J.; Alvarez-Armenta, A.; Sugich-Miranda, R.; Ayala-Zavala, F.; Morales-Ortega, A.; Arvizu-Flores, A. A.; Lopez-Zavala, A. A. Inhibition Mechanism of Lecithin-Dependent Hemolysin from Vibrio parahaemolyticus by Flavonoids: An Enzyme Kinetic and Structural Approach. Catalysts 2025, 15, 257. doi:10.3390/catal15030257
• Chambial, P.; Thakur, N.; Bhukya, P. L.; Subbaiyan, A.; Kumar, U. Frontiers in superbug management: innovating approaches to combat antimicrobial resistance. Archives of microbiology 2025, 207, 60. doi:10.1007/s00203-025-04262-x
• Beshr, G.; Sikandar, A.; Gläser, J.; Fares, M.; Sommer, R.; Wagner, S.; Köhnke, J.; Titz, A. A fucose-binding superlectin from Enterobacter cloacae with high Lewis and ABO blood group antigen specificity. The Journal of biological chemistry 2024, 301, 108151. doi:10.1016/j.jbc.2024.108151
• Zahorska, E.; Denig, L. M.; Lienenklaus, S.; Kuhaudomlarp, S.; Tschernig, T.; Lipp, P.; Munder, A.; Gillon, E.; Minervini, S.; Verkhova, V.; Imberty, A.; Wagner, S.; Titz, A. High-Affinity Lectin Ligands Enable the Detection of Pathogenic Pseudomonas aeruginosa Biofilms: Implications for Diagnostics and Therapy. JACS Au 2024, 4, 4715–4728. doi:10.1021/jacsau.4c00670
• Baumgarten, J.; Schneider, P.; Thiemann, M.; Zimmermann, M.; Diederich, C.; Blankenfeldt, W.; Kunick, C. Substrate-Based Ligand Design for Phenazine Biosynthesis Enzyme PhzF. ChemMedChem 2024, 19, e202400466. doi:10.1002/cmdc.202400466
• Beshr, G.; Sikandar, A.; Gläser, J.; Fares, M.; Sommer, R.; Wagner, S.; Köhnke, J.; Titz, A. A fucose-binding superlectin from Enterobacter cloacae with high Lewis and ABO blood group antigen specificity. openRxiv 2024. doi:10.1101/2024.10.01.616118

Explore citations to this article at